Precision Biosensor
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Precision Biosensor makes portable, rapid diagnostic test devices and cartridges that detect disease markers, such as those for heart attacks, infectious diseases, and brain conditions, directly at the point of care, delivering results within minutes.
Its products are designed for use in hospitals and clinical settings, and it supplies both human and veterinary diagnostic instruments. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company's entire product portfolio is built around point-of-care testing, with its core platform using a time-resolved fluorescence imaging technology originally derived from satellite camera optics.
Summary is AI-generated and may contain errors · figures from DART filings
The company holds Nano-Ditech, a US-based immunodiagnostic cartridge developer and manufacturer, as a wholly owned subsidiary.
Precision Biosensor in five facts
What does Precision Biosensor do?
Precision Biosensor makes portable, rapid diagnostic test devices and cartridges that detect disease markers, such as those for heart attacks, infectious diseases, and brain conditions, directly at the point of care, delivering results within minutes.
Where is Precision Biosensor listed and in which sector?
Precision Biosensor (Korean name: 프리시젼바이오) trades under KRX code 335810 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is Precision Biosensor?
Its market capitalisation was US$24.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Precision Biosensor's latest annual revenue and operating profit?
For fiscal year 2025, Precision Biosensor reported revenue of US$15M, an operating loss of US$4.1M and a net loss of US$7.6M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 4.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Early redemption of convertible bonds (incl. overseas CBs)
Precision Biosensor acquired US$1.98M face value of its 2nd convertible bonds before maturity on 2026-08-18 for US$2.15M, following a bondholder's exercise of the early redemption right, reducing the outstanding face value to zero.
Capital raise · Aug 18 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · May 15
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · May 8
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Precision Biosensor reported consolidated results for FY2025: revenue of US$13.6M (+4.1% year on year), an operating loss of US$3.67M and a net loss of US$6.84M.
Earnings · Mar 10 - [Amended] Completion report on merger, etc. (merger)M&A · Feb 25 · 2 versions
- [Amended] Material event report (merger)M&A · Feb 25
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Feb 19